IMMUNIC CFO granted options on 120,000 shares

Rhea-AI Filing Summary

IMMUNIC, INC. Chief Financial Officer Glenn Whaley received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $11.60 per share and expire on April 2, 2036. The award was approved in connection with an amendment to the company’s 2019 Omnibus Equity Incentive Plan that stockholders approved at the 2026 Annual Meeting of Stockholders held on June 29, 2026. The underlying shares vest 25% on April 2, 2027, with the remaining portion vesting in equal monthly installments over the next 36 months. Following this grant, Whaley holds 120,000 options directly.

Insider Trade Summary

Grant/Award: 120,000 shares

Grant/Award 1 txn

Insider Whaley Glenn

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	120,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 120,000 contracts (Direct)

Footnotes (2)

1. F1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.
2. F2. The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Key Figures

Option grant size: 120,000 shares Exercise price: $11.60 per share Expiration date: April 2, 2036 +3 more

6 metrics

Option grant size 120,000 shares Underlying common stock for new stock option award

Exercise price $11.60 per share Strike price of granted stock options

Expiration date April 2, 2036 Option term end date

Initial vesting 25% Vests on April 2, 2027

Remaining vesting period 36 months Monthly vesting after April 2, 2027

Options owned after grant 120,000 options Total derivative securities following transaction

Key Terms

Stock Option, 2019 Omnibus Equity Incentive Plan, Annual Meeting of Stockholders, vest

4 terms

Stock Option financial

"Represents options to purchase shares of common stock conditionally approved"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2019 Omnibus Equity Incentive Plan financial

"subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan"

Annual Meeting of Stockholders financial

"obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026"

vest financial

"The shares underlying this option vest 25% on April 2, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IMMUNIC (IMUX) CFO Glenn Whaley report on this Form 4?

Glenn Whaley reported receiving a grant of stock options for 120,000 IMMUNIC common shares. These options were awarded as compensation and give him the right to buy shares at a fixed exercise price in the future, subject to the stated vesting schedule.

How many IMMUNIC (IMUX) shares are covered by Glenn Whaley’s new stock options?

The option grant covers 120,000 shares of IMMUNIC common stock. This figure represents the full number of underlying shares tied to the award as reported, and matches his total options beneficially owned following the transaction.

What is the exercise price and expiration date of Glenn Whaley’s IMMUNIC options?

The stock options have an exercise price of $11.60 per share and expire on April 2, 2036. This means he can buy IMMUNIC shares at $11.60, once vested, any time before the stated expiration date.

How do Glenn Whaley’s IMMUNIC (IMUX) options vest over time?

The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months. This creates a four-year vesting period that encourages longer-term alignment with IMMUNIC’s performance.

Were there any conditions tied to IMMUNIC CFO Glenn Whaley’s option grant?

Yes. The options were conditionally approved by IMMUNIC’s Board of Directors, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan. Stockholders granted this approval at the 2026 Annual Meeting of Stockholders on June 29, 2026.

Is Glenn Whaley’s Form 4 transaction a market purchase or sale of IMMUNIC shares?

No. The filing reports a grant of stock options as compensation, coded as an acquisition (A) of a derivative security. It does not reflect an open-market purchase or sale of IMMUNIC common stock in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Whaley Glenn

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$11.6	06/29/2026		A		120,000(1)		(2)	04/02/2036	Common Stock	120,000	$0.00	120,000	D

Explanation of Responses:

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

2. The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

	/s/ Glenn Whaley	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)